BRD4 and other BET proteins have been implicated in the upregulation of inflammatory genes in CKD, and BET inhibitors have been studies in preclinical setting for treatment of kidney injury and prevention of renal fibrosis (31). This evidence concerns the gene BRD4 and chronic kidney disease.